Project Grant HT9425261E253
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $1.73 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2025 through August 31, 2028. The research project focuses on investigating the role of specific long non-coding RNAs (lncRNAs) in combined therapeutic approaches to modulate the thrombospondin-1 (TSP1)-dependent immune microenvironment...
- This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.1M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026 through May 31, 2030. The award supports research defining a retinoblastoma (RB) functional subtype of endometrial cancer, contributing to the DHA's mission to transform healthcare for service members and the American public through innovative biomedical...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $2.0 million project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded September 30, 2026, with a performance period extending through September 29, 2030. The award supports the Prostate Cancer Clinical Trials Consortium, which will be conducted at DFCI's Boston, Massachusetts location. Under this funding mechanism, DFCI will deliver...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $560,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2026, through August 31, 2028. The award supports the development of novel digenic combination therapies for pancreatic cancer treatment, representing a two-year research initiative conducted at DFCI's Boston, Massachusetts facility. This project...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Massachusetts General Hospital a $3.5 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2030. The award supports development and validation of the HEP B-HOST Junction Test, a blood-based biomarker assay designed for early detection of primary and recurrent hepatitis B-related hepatocellular carcinoma. This research initiative aligns with the...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology, received a $168,042 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, with completion scheduled for July 31, 2026. The award supports research focused on in vivo targeting of TFE3 (Transcription Factor E3) dimerization partners in translocation renal cell carcinoma (RCC). This...
- Federal Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2026. This award supports research investigating the interactions of mitochondrially encoded Complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to advance...